PET Scan as a Screening Tool for Liver Transplant in Patients With Hepatocellular Carcinoma (HCC)

N/ACompletedNCT01320852

McGill University Health Centre/Research Institute of the McGill University Health Centre100 enrolled

Overview

This study aims at testing the utility of PET Scan as a screening tool for liver transplantation in patients with Hepatocellular Carcinoma. Patients being worked up for liver transplant for hepatocellular carcinoma will undergo a PET Scan and will be followed until 2 years after transplantation. At that time survival data will be analysed according to PET Scan results to determine if it can be used to predict outcome.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Masking

NONE

Enrollment

100

Conditions

Hepatocellular Carcinoma

Interventions

PET ScanOTHER

All patients will have a PET scan as part of their pre-transplant assessment

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male or female patient over 18 years of age * Diagnosis of HCC confirmed by histology if available or by two imaging modalities * Able to give written informed consent prior to any study specific screening procedures with the understanding that the patient has the right to withdraw from the study at any time, without prejudice. Exclusion Criteria: * Unable to give consent to the study * Unable to undergo a PET Scan

Locations (1)

McGill Univeristy Health Centre

Montreal, Quebec, Canada

Outcomes

Primary Outcomes

Overall Survival

The primary objective of the study is to compare, according to PET scan results, the post-transplantation overall survival of patients meeting Milan criteria to those not meeting Milan criteria

Time frame: up to death

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.